We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Soluble suppression of tumourigenicity 2 as a predictor of postoperative hepatic failure.
- Authors
Wu, Jing; Apaer, Shadike; Fulati, Xiapukaiti; Vuitton, Dominique A; Zhang, Yunfei; Payiziwula, Jiangduosi; Anweier, Nuerzhatijiang; Li, Tao; Tuerxun, Kahaer; Aji, Tuerganaili; Zhao, Jinming; Shao, Yingmei; Tuxun, Tuerhongjiang; Wen, Hao
- Abstract
Background Posthepatectomy liver failure remains a potentially life-threatening complication after hepatectomy. Soluble suppression of tumourigenicity 2 is an injury-related biomarker. The aim of the study was to assess soluble suppression of tumourigenicity 2 elevation after hepatectomy and whether it can predict posthepatectomy liver failure. Methods This was a single-centre retrospective study including all patients who underwent a liver resection between 2015 and 2019. Plasma concentrations of soluble suppression of tumourigenicity 2 were measured before surgery and at postoperative days 1, 2, 5 and 7. Posthepatectomy liver failure was defined according to the International Study Group of Liver Surgery and the morbidity rate was graded according to the Clavien–Dindo classification. Results A total of 173 patients were included (75 underwent major and 98 minor resection); plasma levels of soluble suppression of tumourigenicity 2 increased from 43.42 (range 18.69–119.96) pg/ml to 2622.23 (range 1354.18–4178.27) pg/ml on postoperative day 1 (P < 0.001). Postoperative day 1 soluble suppression of tumourigenicity 2 concentration accurately predicted posthepatectomy liver failure ≥ grade B (area under curve = 0.916, P < 0.001) and its outstanding performance was not affected by underlying disease, liver pathological status and extent of resection. The cut-off value, sensitivity, specificity, positive predictive value and negative predictive value of postoperative day 1 soluble suppression of tumourigenicity 2 in predicting posthepatectomy liver failure ≥ grade B were 3700, 92%, 85%, 64% and 97% respectively. Soluble suppression of tumourigenicity 2high patients more frequently experienced posthepatectomy liver failure ≥ grade B (64.3% (n = 36) versus 2.6% (n = 3)) and Clavien–Dindo IIIa higher morbidity rate (23.2% (n = 13) versus 5.1% (n = 6)) compared with soluble suppression of tumourigenicity 2low patients. Conclusions Soluble suppression of tumourigenicity 2 may be a reliable predictor of posthepatectomy liver failure ≥ grade B as early as postoperative day 1 for patients undergoing liver resection. Its role in controlling hepatic injury/regeneration needs further investigation. Registration number: ChiCTR-OOC-15007210 (www.chictr.org.cn/).
- Subjects
LIVER failure; LIVER surgery; HEPATECTOMY
- Publication
BJS Open, 2024, Vol 8, Issue 3, p1
- ISSN
2474-9842
- Publication type
Article
- DOI
10.1093/bjsopen/zrae043